文献速递产科母胎医学

口服益生菌对妊娠期糖尿病女性血糖控制的影响——一项多中心、随机、双盲、安慰剂对照试验

The effect of oral probiotics on glycemic control of women with gestational diabetes mellitus-a multicenter, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-11-12

这项多中心前瞻性随机双盲安慰剂对照试验纳入新诊断妊娠期糖尿病女性,比较口服益生菌配方与安慰剂对血糖控制及妊娠结局的影响。益生菌组与安慰剂组在治疗2周后需药物治疗的比例、平均每日血糖及餐前餐后血糖均无显著差异,母儿结局亦无差异。

要点

  • 益生菌组与安慰剂组治疗2周后需药物治疗比例分别为59%与41%,差异无统计学意义(P=.10)。
  • 益生菌组与安慰剂组治疗前2周平均每日血糖分别为99.7±7.9与98.0±9.3 mg/dL,差异无统计学意义(P=.35)。
  • 两组整个研究期间餐前及餐后血糖相似(P>.05),母儿结局包括出生体重及不良反应谱无差异。

核心结论

  • 本研究所测试的口服益生菌产品未影响妊娠期糖尿病女性的血糖控制。

研究设计与样本

  • 多中心前瞻性随机双盲安慰剂对照试验,新诊断妊娠期糖尿病女性随机分入研究组(口服益生菌配方2粒/日,含双歧杆菌、乳酸菌和链球菌热菌,>6×10^9/粒)或对照组(安慰剂2粒/日),直至分娩。
  • 治疗组41例与安慰剂组44例纳入分析。

主要发现

  • 治疗前2周平均每日血糖在益生菌组与安慰剂组分别为99.7±7.9与98.0±9.3 mg/dL(P=.35)。
  • 治疗2周后因血糖控制不佳需药物治疗的比例在益生菌组与安慰剂组分别为24例(59%)与18例(41%)(P=.10)。
  • 整个研究期间平均餐前及餐后血糖两组相似(P>.05)。
  • 母儿结局包括出生体重及不良反应谱两组无差异。

临床怎么用

  • 作者结论为研究所测试的口服益生菌产品未影响妊娠期糖尿病女性的血糖控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes mellitus should be treated adequately to avoid maternal hyperglycemia-related complications. Previously, probiotic supplements were suggested to improve fasting blood glucose in women with gestational diabetes mellitus. However, a major limitation of previous studies was that preprandial and especially postprandial glucose values, which are important predictors of pregnancy outcomes, were not studied. OBJECTIVE: This study aimed to examine the effect of a mixture of probiotic strains on maternal glycemic parameters, particularly preprandial and postprandial glucose values and pregnancy outcomes among women with gestational diabetes mellitus. STUDY DESIGN: A multicenter prospective randomized, double-blind, placebo-controlled trial was conducted. Women newly diagnosed with gestational diabetes mellitus were randomly allocated into a research group, receiving 2 capsules of oral probiotic formula containing Bifidobacterium bifidum, B lactis, Lactobacillus acidophilus, L paracasei, L rhamnosus, and Streptococcus thermophilus (>6 × 109/capsule), and a control group, receiving a placebo (2 capsules/day) until delivery. Glycemic control was evaluated by daily glucose charts. After 2 weeks, pharmacotherapy was started in case of poor glycemic control. The primary outcomes were the rate of women requiring medications for glycemic control and mean daily glucose charts after 2 weeks of treatment with the study products. RESULTS: Forty-one and 44 women were analyzed in the treatment and placebo cohorts, respectively. Mean daily glucose during the first 2 weeks in the probiotics and placebo groups was 99.7±7.9 and 98.0±9.3 mg/dL, respectively (P=.35). The rate of women needing pharmacotherapy because of poor glycemic control after 2 weeks of treatment in the probiotics and placebo groups was 24 (59%) and 18 (41%), respectively (P=.10). Mean preprandial and postprandial glucose levels throughout the study period were similar between the groups (P>.05). There were no differences in maternal and neonatal outcomes, including birthweight and adverse effect profile between the groups. CONCLUSION: The oral probiotic product tested in this study did not affect glycemic control of women with gestational diabetes mellitus.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Nachum Z, Perlitz Y, Shavit LY, et al. The effect of oral probiotics on glycemic control of women with gestational diabetes mellitus-a multicenter, randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol MFM. 2023. PMID: 37956906. doi:10.1016/j.ajogmf.2023.101224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。